Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
- Dept of Biochemical Engineering
- Faculty of Engineering Science
Tarit conducted his undergraduate studies in Biochemical Engineering at UCL and his Masters at the University of Massachusetts, Amherst.
He conducted his engineering doctorate in a joint venture between UCL and the Health Protection Agency, working on 2 vaccine of commercial interest, a novel Meningitis B vaccine based upon the outer membrane proteins of N.lactamica and the UK licensed Anthrax vaccine. As part of his doctoral studies in a joint project with the Health Protection Agency and Prof Gary Lye in the IMRC in Bioprocessing, Tarit focused on the development of a microwell platform for rapid vaccine development. This platform was applied to the development of a new Meningitis B vaccine now in clinical trials. The platforms usefulness and robustness was also tested with the UK Anthrax Vaccine, (AVP) – utilised to gather deeper process insight under ACDP Class 3 conditions.
Shortly after completing his doctorate he was appointed lecturer in the Department of Biochemical Engineering, UCL, where he heads up the new vaccine bioprocess research portfolio and has an interest in virus vaccines. He is currently working on Japanese Encephalitis virus vaccine, Hepatitis B, and the use of Lentiviruses for Gene Therapy, with an interest in upstream, downstream processing and PAT.
Tarit's previous experience is in protein and bacterial vaccines (Meningitis B and the UK licensed Anthrax vaccine) with the Health Protection Agency, Porton Down. He now primarily works on virus and virus-like particle processes. This includes cell expression and induction, Up Stream Processing, Inactivation, Down Stream Processing studies looking at filtration, formulation and chromatography. A new focus has been conjugate vaccines.
The primary methodology is to create scale-down models that mimic the processing environment to determine CQA/CPP that can be accurately applied to the commercial scale. The obvious benefits being speed, (reducing time to market) and cost. Other interests are hydrodynamic and physiological effects on antigen recovery on potency, such as shear and aggregation effects.
Intercell Biomedical, Oxford Biomedica, Pfizer, London Centre for Nanotechnology, GSK, iQur
Tarit is responsible for co-ordination of all vaccine related teaching activities across the Department. The possibilities of an AIDS vaccine have been met with increased scientific and media interest and Tarit challenges his 1st year undergraduates to consider the possibilities of an AIDS vaccine, its delivery, distribution and financing.
He also delivers a series of lectures to MEng and Msc students regarding the latest advanced in vaccine technology as well as the ethics and economics of vaccine development.
Tarit also run a CPD training course in “Vaccine Bioprocess Development and Commercialisation" in December. This is a 3 day course with case-studies and industrial speakers on topics related to vaccine development, formulation and analytics. The course is ideal for those who are just entering the vaccine sector or would like technical briefings by industry experts. More information available at www.ucl.ac.uk/biochemeng/industry/mbi/courses/VBDC.
|2008||EngD||Doctor of Engineering – Biochemical Engineering||University College London|
|2002||MEng||Master of Engineering – Biochemical Engineering||University College London|